Author

Akiko Chai 1

1 Genentech Inc.,South San Francisco, CA,United States

ETROLIZUMAB AS INDUCTION AND MAINTENANCE THERAPY IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO ANTI-TUMOR NECROSIS FACTOR AGENT: THE RANDOMIZED, PHASE 3 HICKORY TRIAL

Laurent Peyrin-Biroulet, Ailsa L Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward V Loftus Jr, Elham Ostad-Saffari, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William Sandborn

ETROLIZUMAB COMPARED WITH ADALIMUMAB OR PLACEBO AS INDUCTION THERAPY FOR ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED, PHASE 3 HIBISCUS I & II TRIALS

Iris Dotan, Julian Panés, Aaron Duvall, Yoram Bouhnik, Graham Radford-Smith, Peter D.R. Higgins, Daniel S. Mishkin, Pablo Arrisi, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, David T. Rubin

ETROLIZUMAB TREATMENT INCREASES BLOOD LEVELS OF CD3, TREG AND TH17 CELLS MEASURED THROUGH EPIGENETIC ACTIVATION OF THE CD3, FOXP3 AND IL-17 LOCI

Franklin Fuh, Eva Raschke, Akiko Chai, Caroline Looney, Thomas Oliver Kleen, Severine Vermeire, Sharon O'Byrne, Teresa Ramirez Montagut

ETROLIZUMAB VERSUS INFLIXIMAB FOR TREATING PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 GARDENIA STUDY

Silvio Danese, Jean-Frederic Colombel, Milan Lukas, Javier Gisbert, Geert R. D'Haens, Bu Hayee, Remo Pannacione, Hyun-Soo Kim, Walter Reinisch, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Meina Tao Tang, Stefan Schreiber

ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL

Severine Vermeire, Peter L Lakatos, Timothy Ritter, Stephen B Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Khavarian Kadva, Helen Tyrrell, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Wenhui Zhang, Brian G. Feagan

Item 1 - 5 / 5
1